Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 3/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.36 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | SGK1 | O00141 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591678 | 0.90 | CD38 (0.38) | CD38RPS6KA5RPS6KA4SGK1ALDH1A1 | |
| SCHEMBL7595473 | 0.87 | MEN1 (0.42) | CD38RPS6KA5RPS6KA4ALPLSGK1 | |
| SCHEMBL7590764 | 0.85 | ALDH1A1 (0.41) | CD38RPS6KA5RPS6KA4CYP3A4ALDH1A1 | |
| SCHEMBL7590558 | 0.85 | FFAR4 (0.39) | CD38ACLYFFAR4ALPLALDH1A1 | |
| SCHEMBL7595198 | 0.82 | TRPV1 (0.38) | CD38RPS6KA5ACLYFFAR4ALPL | |
| SCHEMBL7588771 | 0.75 | MEN1 (0.45) | ALPLALDH1A1HPGDGAAPTGS2 | |
| SCHEMBL7589681 | 0.75 | MEN1 (0.44) | FFAR4ALDH1A1HPGDKITGAA | |
| SCHEMBL7595027 | 0.74 | MAPT (0.41) | RPS6KA5RPS6KA4CYP3A4ALDH1A1HPGD | |
| SCHEMBL7591276 | 0.72 | MEN1 (0.46) | CYP3A4ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL594070 | 0.72 | MAPT (0.41) | RPS6KA5RPS6KA4ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | CD38 2698/4885RPS6KA5 300/4885RPS6KA4 235/4885 |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | CD38 1852/4885RPS6KA5 338/4885RPS6KA4 330/4885 |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | CD38 2698/4885RPS6KA5 300/4885RPS6KA4 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.